UK markets closed
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • FTSE 250

    22,324.19
    -210.95 (-0.94%)
     
  • AIM

    1,229.80
    -11.57 (-0.93%)
     
  • GBP/EUR

    1.1636
    -0.0053 (-0.46%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • BTC-GBP

    25,798.77
    +19.16 (+0.07%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • DOW

    33,290.08
    -533.37 (-1.58%)
     
  • CRUDE OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD FUTURES

    1,763.90
    -10.90 (-0.61%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     
  • HANG SENG

    28,801.27
    +242.68 (+0.85%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • CAC 40

    6,569.16
    -97.10 (-1.46%)
     

Global Sickle Cell Anemia Market Report 2021-2031: Key Marketed and Pipeline Drugs, Clinical Trials, Recent Events, Regulatory Events, Success Probability, Disease Prevalence, Licensing & Acquisition

·3-min read

Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Sickle Cell Anemia" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

  • Using an estimated global prevalence of 0.04%, the publisher approximated that there were 3.3 million prevalent cases of sickle cell anemia worldwide in 2019. Africa is estimated to account for 85% of worldwide cases.

  • The approved drugs in the sickle cell anemia space target selectins, fetal hemoglobin, nicotinamide adenine dinucleotide, and hemoglobin. These drugs are administered via the oral route, except for Adakveo, which is available as an intravenous formulation.

  • The largest proportion of industry-sponsored drugs in active clinical development for sickle cell anemia are in Phase I. Therapies in development for sickle cell anemia focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral and subcutaneous formulations.

  • High-impact upcoming events for drugs in the sickle cell anemia space comprise topline Phase IIb trial results for IMR-687, and an expected CHMP opinion for Oxbryta.

  • The overall likelihood of approval of a Phase I hematology asset is 24.8%, and the average probability a drug advances from Phase III is 75.5%. Drugs, on average, take 9.2 years from Phase I to approval in the overall hematology space.

  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for sickle cell anemia have been in the early and mid-phases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

  • The US has a substantial lead in the number of sickle cell anemia clinical trials globally. The UK leads the major European markets, while Lebanon has the top spot in Asia.

  • Clinical trial activity in the sickle cell anemia space is dominated by completed trials. Global Blood Therapeutics has the highest number of completed clinical trials for sickle cell anemia, with 10 trials.

  • Global Blood Therapeutics leads industry sponsors with the highest overall number of clinical trials for sickle cell anemia, followed by Novartis

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Bone marrow transplantation

  • Hydroxyurea

  • Blood transfusions

  • Prophylactic therapy

  • Pain management

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Zynteglo for Sickle Cell Anemia (February 16, 2021)

  • IMR-687 for Sickle Cell Anemia (January 6, 2021)

  • Multiple Drugs for Sickle Cell Anemia (December 7, 2020)

  • IMR-687 for Sickle Cell Anemia (June 12, 2020)

  • IMR-687 for Sickle Cell Anemia (February 14, 2020)

  • CTX001 for Sickle Cell Anemia (November 19, 2019)

  • Rivipansel for Sickle Cell Anemia (August 2, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • New Therapeutic Targets & a Rich Year for Approvals: EMA's PRIME in 2020

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Pfizer Ends Pact with GlycoMimetics After SCD Failure

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/wf6hbl

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting